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Paclitaxel-induced severe hyper­
sensitivity reaction occurring 
as a late toxicity
Severe hypersensitivity reactions (HSRs) have been observed 
after the administration of paclitaxel (Taxol0), and attributed 
to the drug’s pharmaceutical vehicle, 50% Cremophor EL
1 j. The prophylactic use of steroids and histamine antago­
nists has reduced the incidence of HSRs to about 2%. All 
HSRs described to date have occurred during either the first 
or second courses of paclitaxel administration [1,2].
We treated a 67-year-old male with advanced non-small- 
cell lung cancer with a combination of cisplatin (80 mg/m2) 
and paclitaxel (175 m g/m 2, 3-hour infusion) once every 3 
weeks according to a study protocol (EORTC 08925). He 
was not known to have chronic obstructive pulmonary dis­
ease. Premedication consisted of dexamethasone 20 mg oral- 
ly 12 and 6 hours prior to paclitaxel infusion, and clemas- 
tinefumurate 2 mg i.v. and famotidine 40 mg i.v. 30 minutes 
prior to paclitaxel infusion.
Six days after his first infusion with paclitaxel he devel­
oped a supraventricular tachycardia. A  cardiac ultrasound 
showed no abnormalities. Sotalol 80 mg two times daily was 
started. Cisplatin was discontinued after two cycles due to a 
reversible rise in serum creatinine. From the second cycle on 
our patient had a transient rise in blood pressure during 
paclitaxel infusion and his blood pressure was periodically 
elevated between infusions. At the start of the sixth cycle his 
blood pressure was 140/90 mm Hg, and four hours after the 
start of infusion of paclitaxel he developed an acute life- 
threatening dyspnoea. No pmritis or urticaria were observed. 
Physical examination showed a blood pressure of 200 /120  
mm Hg, a pulse rate of 76/minute and a normal central 
venous pressure. He was breathing 36 to 50 times per mi­
nute. Cardiac auscultation was normal, Over both lungs a 
prolonged wheezing and rhonchi were heard, but no crepita­
tions. There was no peripheral edema. The electrocardio­
gram was normal. An arterial bloodgas showed a pH 7.35, 
p C 0 2 39.5 mm Hg, p 0 2 47.2 mm Hg and bicarbonate 21.9 
mmol/1. A chest X-ray showed marked bilateral pulmonary
edema. He was treated with adrenaline 0.5 mg i.m. twice, 
dexamethasone 20 mg i.v., clemastinefumurate 2 mg i.v., 
aminophylline 240 mg as loading dose and 720 mg/24 hours 
as maintenance dose i.v., furosemide 80 mg i.v., oxygen 5 
1/min and salbutamol combined with ipratropiumbromide 
inhalation. After 40 minutes his condition improved, and 
eventually, he recovered completely.
We conclude that our patient had a life-threatening HSR 
with severe bronchospasm, hypertension and pulmonary 
edema during his sixth cycle of paclitaxel. Only a single case 
of paclitaxel-related pulmonary edema has been reported [3]. 
The supraventricular tachycardia, which occurred after the 
first cycle, may also have been caused by paclitaxel [4], There 
is evidence that ß-blockers increase the sensitivity to aller­
gens by competitive inhibition at the ß-adrenergic receptor 
site. This may result in a decrease in intracellular levels of 
cyclic AMP which lowers the threshold of mediator release 
by mast cells and basophils [5J. Thus, the so ta loi may have 
potentiated the HSR in our patient.
In the absence of an elevated central venous pressure and 
peripheral edema, it is not likely that congestive heart failure 
was the underlying cause of the pulmonary edema we ob­
served. The absence of angioedema and urticaria do not indi­
cate an increased vascular permeability. The blood pressure 
measured during this event suggests vasoconstriction. Thus, 
the lung edema seems to have resulted from a selective reac­
tion of the pulmonary vascular bed to the permeability- 
enhancing activity of paclitaxel and/or its pharmaceutical 
vehicle.
Due to the late occurrence of HSR in our patient, routine 
observation for several hours after each infusion of all 
patients treated with paclitaxel may be warranted.
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